A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) is a phase 3 interventional study registered as NCT06698042 by Merck Sharp & Dohme LLC, with 67 participants enrolled, started 2024-11-21 and due to reach its primary completion in 2026-03-12. Interventions recorded: Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab. Conditions listed: Lung Cancer, Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPlacebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer.
- TrialA Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I
Shares Merck & Co. (MSD), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Merck & Co. (MSD), Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.